<DOC>
	<DOCNO>NCT00264914</DOCNO>
	<brief_summary>To determine long-term safety tolerability SR121463B patient syndrome inappropriate antidiuretic secretion ( SIADH ) . To assess long-term efficacy SR121463B maintain normal level serum sodium patient SIADH . Long term safety evaluate open label extension study flexible dos satavaptan .</brief_summary>
	<brief_title>Safety Efficacy SR121463B Patients With Syndrome Inappropriate Antidiuretic Hormone Secretion</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Inappropriate ADH Syndrome</mesh_term>
	<mesh_term>Diabetes Insipidus</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Vasopressins</mesh_term>
	<mesh_term>Arginine Vasopressin</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Male female patient age 18 year higher . SIADH ( diagnosis SIADH base several criterion include true serum hypoosmolality , inappropriate urinary osmolality , clinical euvolemia , elevate urinary sodium excretion normal salt water intake , normal renal , adrenal , thyroid function : drug induce SIADH limit carbamazepine derivative antidepressant patient drug discontinue easily replace drug ) Serum sodium 115 132 mmol/L ( least two consecutive serum sodium level least 24 hour apart , Day 6 Day 1 ) ; sodium level 125 132 mmol/L , spontaneous serum sodium increase two assessment Day 1 &lt; 4 mmol/L Urinary osmolality &gt; 200mOsm/kg H2O Urinary sodium &gt; 30 mmol/L Patients acute postoperative SIADH Presence dilutional hyponatremia hypervolemic state congestive heart failure liver disease ascites Presence sign hypovolemia ( e.g. , orthostatic hypotension , increase serum urea nitrogen , increase serum albumin , increase hematocrit , … ) Administration V2 receptor antagonist demeclocycline lithium within one month , thiazide diuretic spironolactone within 15 day , urea loop diuretic within two day prior study drug administration Patients know treat untreated adrenal deficiency Presence untreated hypothyroidism Presence uncontrolled diabetes fast glycemia &gt; 200 mg/dL ( &gt; 11.09 mmol/L ) Presence clinical and/or electrocardiographical sign acute myocardial infarction acute ischemia , clinically significant abnormality accord Investigator 12 lead ECG record Administration inducer CYP3A4 ( phenytoin , rifampin , Saint John 's Wort ) potent moderate inhibitor CYP3A4within two week prior study drug administration Inadequate hematological , renal hepatic function ; hemoglobin ( Hb ) &lt; 9 g/dL , neutrophils &lt; 1,500/mm3 , platelet &lt; 100,00/mm3 , serum creatine &gt; 175 µmol/L ( clearance creatine &lt; 30mL/min Ethics Committees require parameter ) , ALT /or AST &gt; 2x upper limit normal QTcB &gt; 500 m Serum potassium &gt; 5 mmol/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Inappropriate ADH Syndrome</keyword>
	<keyword>Hyponatremia</keyword>
</DOC>